key: cord-0690631-86t33mgo
authors: Kazama, Shingo; Okumura, Takahiro; Kimura, Yuki; Ito, Ryota; Araki, Takashi; Mizutani, Takashi; Oishi, Hideo; Kuwayama, Tasuku; Hiraiwa, Hiroaki; Kondo, Toru; Morimoto, Ryota; Saeki, Tomoaki; Murohara, Toyoaki
title: Biopsy-proven Fulminant Myocarditis Requiring Mechanical Circulatory Support Following COVID-19 mRNA Vaccination
date: 2022-02-13
journal: CJC Open
DOI: 10.1016/j.cjco.2022.02.004
sha: 6bbc80c00c5f02e6c9e958f3b36ec2f7f800ff01
doc_id: 690631
cord_uid: 86t33mgo

A 48-year-old woman suffered from cardiogenic shock with fulminant myocarditis following the second dose of COVID-19 vaccine (mRNA-1273). Venoarterial extracorporeal membrane oxygenation and Impella® support were essential in achieving hemodynamic stability. Endomyocardial biopsy revealed lymphocytic infiltration with predominant immunostaining for CD8 and CD68 positive cells. Left ventricular ejection fraction improved significantly after treatment with mechanical circulatory support. Myocarditis following COVID-19 mRNA vaccination may also occur in middle-aged women; it may be fulminant and require mechanical circulatory support. Although our results suggest the involvement of cytotoxic T lymphocytes and macrophages, further investigations are needed before establishing this pathogenetic mechanisms.

A 48-year-old woman experienced persistent malaise for 1 week after receiving the 10 second dose of the Moderna COVID-19 (mRNA-1273) vaccine; dyspnea appeared on the 7 th 11 day following vaccination. Her symptoms did not improve, and she was taken to the emergency 12 department of her local hospital on the 9 th day. The second dose was administered 28 days after 13 the first, and she had also experienced malaise after the first dose, which had resolved Figure 1A ). Echocardiography showed a diffusely decreased left ventricular 9 ejection fraction (LVEF) of 11%, and right ventricular contraction was also markedly decreased. Figure 1C-H) . Histopathological findings showed no giant cells or frequent eosinophils; 13 therefore, immunotherapy was not administered. On day 4, because LVEF improved to 32.6 % 14 and CK, AST, ALT, and LDH were also improving, VA-ECMO was removed (Figure 2) . On 15 day 5, Impella CP was removed, and the patient was extubated. On day 7, the patient was 16 transferred from the intensive care unit to the general ward. Dobutamine was tapered off and 17 discontinued on day 8. Echocardiography on day 17 showed that LVEF had improved to 59.8%, 18 with no significant valvular disease (Supplemental Video 2) . Additionally, cardiac MRI performed on day 21 showed no abnormalities, so we decided to monitor the patient carefully 1 without introducing cardioprotective drugs such as an angiotensin converting enzyme inhibitor 2 or a beta blocker. A PCR test of EMB specimens did not detect any viral genomes, such as With the widespread use of COVID-19 mRNA vaccines, post-vaccination myocarditis 10 is attracting attention. It is conventionally known to be more common in young males under 11 30 years of age and is more common after the second dose than the first; in many cases, these 12 complications occur within a week of vaccination. 1 Moreover, disease severity has been 13 reported to be mild in most cases, and cases requiring MCS are very rare. Although the Lake Histopathology of the myocardium in our case showed inflammatory cell infiltration, mainly 14 lymphocytes, with some cytotoxicity. Immunostaining showed that the staining for CD8 was 15 more positive than that for CD4; moreover, the staining for CD68 was positive, suggesting that 16 cytotoxic T lymphocytes and macrophages may be largely involved in myocardial 17 inflammation. In a case report showing the histopathology of fulminant lymphocytic 18 myocarditis (not following COVID-19 vaccination), the myocardium was infiltrated with CD8-also not been established. The patient in this case was able to wean off mechanical circulatory 1 support in a relatively short period of time, even though it was initially lethal. Previous reports 2 have suggested that left ventricular unloading with Impella suppresses inflammatory cell 3 infiltration in fulminant myocarditis. 8 We speculated that, also in this case, left ventricular 4 unloading by early introduction of Impella CP may have suppressed inflammatory cell 5 infiltration, and improved left ventricular contraction in a relatively short period. Therefore, 6 early introduction of mechanical circulatory support with left ventricular unloading is 7 important in fulminant myocarditis. The exact mechanism is still unclear and more cases need 8 to be accumulated, however this report helps confirm that classic lymphocytic fulminant 9 myocarditis can be triggered by a COVID-19 mRNA vaccine. 14 (It should be noted that troponin was measured as troponin I at the prior hospital.)

Myocarditis with COVID-19 mRNA vaccines

Cedar et al, Myocarditis after BNT162b2 mRNA vaccine against 4

Covid-19 in Israel

Mode-of-action of the PROPELLA concept 2 in fulminant myocarditis